Selective blockade of CD28-mediated T cell costimulation protects rhesus monkeys against acute fatal experimental autoimmune encephalomyelitis

Journal of Immunology

Volumn 194, Issue 4, 2015, Pages 1454-1466

  Haanstra, Krista G ^a   Dijkman, Karin ^a   Bashir, Noun ^a   Bauer, Jan ^b   Mary, Caroline ^c   Poirier, Nicolas ^c   Baker, Paul ^d   Scobie, Linda ^d   T'Hart, Bert A ^a,e   Vanhove, Bernard ^c,f  

^a BIOMEDICAL PRIMATE RESEARCH CENTRE   (Netherlands)

^b Medical University of Vienna   (Austria)

^c Effimune SAS   (France)

^d GLASGOW CALEDONIAN UNIVERSITY   (United Kingdom)

^e UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^f INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CD28 ANTIGEN; EOTAXIN; FR 104; GAMMA INTERFERON INDUCIBLE PROTEIN 10; IMMUNOGLOBULIN F(AB) FRAGMENT; INTERLEUKIN 12; INTERLEUKIN 15; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 6; MACROPHAGE DERIVED CHEMOKINE; MONOCYTE CHEMOTACTIC PROTEIN 1; PLACEBO; UNCLASSIFIED DRUG; RECOMBINANT PROTEIN;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTICLE; B LYMPHOCYTE ACTIVATION; BRAIN; CELLULAR IMMUNITY; CEREBROSPINAL FLUID; CONTROLLED STUDY; CROSS REACTION; CYTOMEGALOVIRUS; DEMYELINATION; DRUG BLOOD LEVEL; DRUG TOLERABILITY; EPSTEIN BARR VIRUS; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; IMMUNOGENICITY; IMMUNOPROPHYLAXIS; IN VITRO STUDY; IN VIVO STUDY; LATENT VIRUS INFECTION; MALE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; POLYMERASE CHAIN REACTION; POLYOMA VIRUS; POLYOMA VIRUS SA12; PROTEIN BLOOD LEVEL; QUANTITATIVE ANALYSIS; REGULATORY T LYMPHOCYTE; RHESUS MONKEY; SIMIAN VIRUS 40; SPLEEN; SURVIVAL; T LYMPHOCYTE ACTIVATION; VIRUS REACTIVATION; ANIMAL; ANTAGONISTS AND INHIBITORS; B LYMPHOCYTE; COMPLICATION; HUMAN; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; REAL TIME POLYMERASE CHAIN REACTION; T LYMPHOCYTE; VIROLOGY; VIRUS INFECTION; VIRUS LATENCY;

ANIMALS; ANTIGENS, CD28; B-LYMPHOCYTES; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; HUMANS; LYMPHOCYTE ACTIVATION; MACACA MULATTA; REAL-TIME POLYMERASE CHAIN REACTION; RECOMBINANT PROTEINS; T-LYMPHOCYTES; VIRUS DISEASES; VIRUS LATENCY;

EID: 84922569652     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1402563     Document Type: Article

References (52)

1. Tanaka, Y., S. Kubo, H. Yamanaka, K. Amano, S. Hirata, E. Tanaka, H. Nagasawa, H. Yasuoka, and T. Takeuchi. 2014. Efficacy and safety of aba-tacept in routine care of patients with rheumatoid arthritis: Orencia(®) as Biological Intensive Treatment for RA (ORBIT) study. Mod. Rheumatol 24: 754-762.
2. Viglietta, V., K. Bourcier, G. J. Buckle, B. Healy, H. L. Weiner, D. A. Hafler, S. Egorova, C. R. Guttmann, J. R. Rusche, and S. J. Khoury. 2008. CTLA4Ig treatment in patients with multiple sclerosis: an open-label, phase 1 clinical trial. Neurology 71: 917-924.
3. National Institutes of Health. Clinical Trials database. Available at: http://www.clinicaltrials.gov/ct2/show/study/NCT01116427. Accessed: December 29, 2014.
4. Chang, T. T., C. Jabs, R. A. Sobel, V. K. Kuchroo, and A. H. Sharpe. 1999. Studies in B7-deficient mice reveal a critical role for B7 costimulation in both induction and effector phases of experimental autoimmune encephalomyelitis. J. Exp. Med. 190: 733-740.
5. Chitnis, T., N. Najafian, K. A. Abdallah, V. Dong, H. Yagita, M. H. Sayegh, and S. J. Khoury. 2001. CD28-independent induction of experimental autoimmune encephalomyelitis. J. Clin. Invest. 107: 575-583.
6. Oliveira-dos-Santos, A. J., A. Ho, Y Tada, J. J. Lafaille, S. Tonegawa, T W. Mak, and J. M. Penninger. 1999. CD28 costimulation is crucial for the development of spontaneous autoimmune encephalomyelitis. J. Immunol. 162: 4490-4495.
7. Khoury, S. J., E. Akalin, A. Chandraker, L. A. Turka, P. S. Linsley, M. H. Sayegh, and W. W. Hancock. 1995. CD28-B7 costimulatory blockade by CTLA4Ig prevents actively induced experimental autoimmune encephalomyelitis and inhibits Th1 but spares Th2 cytokines in the central nervous system. J. Immunol. 155: 4521-4524.
8. Perrin, P. J., C. H. June, J. H. Maldonado, R. B. Ratts, and M. K. Racke. 1999. Blockade of CD28 during in vitro activation of encephalitogenic T cells or after disease onset ameliorates experimental autoimmune encephalomyelitis. J. Immunol. 163: 1704-1710.
9. Poirier, N., G. Blancho, and B. Vanhove. 2012. CD28-specific immunomodu-lating antibodies: what can be learned from experimental models? Am. J. Transplant. 12: 1682-1690.
10. Suntharalingam, G., M. R. Perry, S. Ward, S. J. Brett, A. Castello-Cortes, M. D. Brunner, and N Panoskaltsis. 2006. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N. Engl. J. Med. 355: 1018-1028.
11. Poirier, N, C. Mary, N. Dilek, J. Hervouet, D. Minault, G. Blancho, and B. Vanhove. 2012. Preclinical efficacy and immunological safety of FR104, an antagonist anti-CD28 monovalent Fab9 antibody. Am. J. Transplant. 12: 2630-2640.
12. Poirier, N., C. Mary, S. Le Bas-Bernardet, V. Daguin, L. Belarif, M. Chevalier, J. Hervouet, D. Minault, S. Ville, V Charpy, et al. 2014. Advantages of Papio anubis for preclinical testing of immunotoxicity of candidate therapeutic antagonist antibodies targeting CD28. MAbs 6: 697-707.
13. 't Hart, B. A., and L. Massacesi. 2009. Clinical, pathological, and immunologic aspects of the multiple sclerosis model in common marmosets (Callithrix jac-chus). J. Neuropathol. Exp. Neurol. 68: 341-355.
14. Kerlero de Rosbo, N., H. P. Brok, J. Bauer, J. F. Kaye, B. A. 't Hart, and A. Ben-Nun. 2000. Rhesus monkeys are highly susceptible to experimental autoimmune encephalomyelitis induced by myelin oligodendrocyte glycoprotein: characterisation of immunodominant T- and B-cell epitopes. J. Neuroimmunol. 110: 83-96.
15. 7, inhibits leukocytic infiltration of the central nervous system in rhesus monkey experimental autoimmune encephalomyelitis. J. Immunol. 190: 1961-1973.
16. 't Hart, B. A., J. Bauer, H. P. Brok, and S. Amor. 2005. Non-human primate models of experimental autoimmune encephalomyelitis: variations on a theme. J. Neuroimmunol. 168: 1-12.
17. Bellizzi, A., C. Nardis, E. Anzivino, D. Rodìo, D. Fioriti, M. Mischitelli, F Chiarini, and V Pietropaolo. 2012. Human polyomavirus JC reactivation and pathogenetic mechanisms of progressive multifocal leukoencephalopathy and cancer in the era of monoclonal antibody therapies. J. Neurovirol. 18: 1-11.
18. Green, M., and M. G. Michaels. 2013. Epstein-Barr virus infection and post-transplant lymphoproliferative disorder. Am. J. Transplant. 13(Suppl. 3): 41-54, quiz 54.
19. Nakajima, H., A. Takayama, T. Ito, and T Yoshikawa. 2013. Acute encephalomyelitis with multiple herpes viral reactivations during abatacept therapy. BMJ Case Rep. pii: bcr2013009731.
20. Lühder, F., Y. Huang, K. M. Dennehy, C. Guntermann, I. Müller, E. Winkler, T. Kerkau, S. Ikemizu, S. J. Davis, T. Hanke, and T. Hünig. 2003. Topological requirements and signaling properties of T cell-activating, anti-CD28 antibody superagonists. J. Exp. Med. 197: 955-966.
21. + regulatory T cells in rhesus monkeys. Transplantation 85: 1185-1192.
22. Haanstra, K. G., S. A. Jagessar, A. L. Bauchet, M. Doussau, C. M. Fovet, N. Heijmans, S. O. Hofman, J. van Lubeek-Veth, J. J. Bajramovic, Y. S. Kap, et al. 2013. Induction of experimental autoimmune encephalomyelitis with recombinant human myelin oligodendrocyte glycoprotein in incomplete Freund's adjuvant in three non-human primate species. J. Neuroimmune Pharmacol. 8: 1251-1264.
23. Quesgen Systems, Inc. Data management for clinical research. Available at: http://www.quesgen.com/SSSurvival.php. Accessed December 29, 2014.
24. Kerlero de Rosbo, N., M. Hoffman, I. Mendel, I. Yust, J. Kaye, R. Bakimer, S. Flechter, O. Abramsky, R. Milo, A. Karni, and A. Ben-Nun. 1997. Predominance of the autoimmune response to myelin oligodendrocyte glycoprotein (MOG) in multiple sclerosis: reactivity to the extracellular domain of MOG is directed against three main regions. Eur. J. Immunol. 27: 3059-3069.
25. Brok, H. P., L. Boven, M. van Meurs, N. Kerlero de Rosbo, L. Celebi-Paul, Y. S. Kap, A. Jagessar, R. Q. Hintzen, G. Keir, J. Bajramovic, et al. 2007. The human CMV-UL86 peptide 981-1003 shares a crossreactive T-cell epitope with the encephalitogenic MOG peptide 34-56, but lacks the capacity to induce EAE in rhesus monkeys. J. Neuroimmunol. 182: 135-152.
26. Brok, H. P., J. Bauer, M. Jonker, E. Blezer, S. Amor, R. E. Bontrop, J. D. Laman, and B. A. 't Hart. 2001. Non-human primate models of multiple sclerosis. Immunol. Rev. 183: 173-185.
27. Jagessar, S. A., P. A. Smith, E. Blezer, C. Delarasse, D. Pham-Dinh, J. D. Laman, J. Bauer, S. Amor, and B. 't Hart. 2008. Autoimmunity against myelin oligo-dendrocyte glycoprotein is dispensable for the initiation although essential for the progression of chronic encephalomyelitis in common marmosets. J. Neuro-pathol. Exp. Neurol. 67: 326-340.
28. World Health Organization Hepatitis E virus standard for RNA assay. Paul Ehrlich Institute. Available at: http://www.pei.de/EN/information/license-applicants/standard-and-referencematerials/who/hepatitis-e-rna-nat/referencematerial-standard-hepatitis-e-rna-nat-node.html. Accessed December 29, 2014.
29. Cantalupo, P., A. Doering, C. S. Sullivan, A. Pal, K. W. Peden, A. M. Lewis, and J. M. Pipas. 2005. Complete nucleotide sequence of polyomavirus SA12. J. Virol. 79: 13094-13104.
30. Dilek, N., N. Poirier, P. Hulin, F. Coulon, C. Mary, S. Ville, H. Vie, B. Clémenceau, G. Blancho, and B. Vanhove. 2013. Targeting CD28, CTLA-4 and PD-L1 costimulation differentially controls immune synapses and function of human regulatory and conventional T-cells. PLoS One 8: e83139.
31. Poirier, N., A. M. Azimzadeh, T. Zhang, N. Dilek, C. Mary, B. Nguyen, X. Tillou, G. Wu, K. Reneaudin, J. Hervouet, et al. 2010. Inducing CTLA-4-dependent immune regulation by selective CD28 blockade promotes regulatory T cells in organ transplantation. Sci. Transl. Med. 2: 17ra10.
32. Jagessar, S. A., N. Heijmans, E. L. Blezer, J. Bauer, J. H. Blokhuis, J. A. Wubben, J. W. Drijfhout, P. J. van den Elsen, J. D. Laman, and B. A. Hart. 2012. Unravelling the T-cell-mediated autoimmune attack on CNS myelin in a new primate EAE model induced with MOG34-56 peptide in incomplete adjuvant. Eur. J. Immunol. 42: 217-227.
33. Girvin, A. M., M. C. Dal Canto, L. Rhee, B. Salomon, A. Sharpe, J. A. Bluestone, and S. D. Miller. 2000. A critical role for B7/CD28 costimu-lation in experimental autoimmune encephalomyelitis: a comparative study using costimulatory molecule-deficient mice and monoclonal antibody blockade. J. Immunol. 164: 136-143.
34. 't Hart, B. A., B. Gran, and R. Weissert. 2011. EAE: imperfect but useful models of multiple sclerosis. Trends Mol. Med. 17: 119-125.
35. Adams, A. B., M. A. Williams, T. R. Jones, N. Shirasugi, M. M. Durham, S. M. Kaech, E. J. Wherry, T. Onami, J. G. Lanier, K. E. Kokko, et al. 2003. Heterologous immunity provides a potent barrier to transplantation tolerance. J. Clin. Invest. 111: 1887-1895.
36. Williams, M. A., T. M. Onami, A. B. Adams, M. M. Durham, T. C. Pearson, R. Ahmed, and C. P. Larsen. 2002. Cutting edge: persistent viral infection prevents tolerance induction and escapes immune control following CD28/CD40 blockade-based regimen. J. Immunol. 169: 5387-5391.
37. 't Hart, B. A., S. A. Jagessar, K. Haanstra, E. Verschoor, J. D. Laman, and Y. S. Kap. 2013. The primate EAE model points at EBV-infected B cells as a preferential therapy target in multiple sclerosis. Front. Immunol. 4: 145.
38. Lumsden, J. M., J. A. Williams, and R. J. Hodes. 2003. Differential requirements for expression of CD80/86 and CD40 on B cells for T-dependent antibody responses in vivo. J. Immunol. 170: 781-787.
39. Rau, F. C., J. Dieter, Z. Luo, S. O. Priest, and N. Baumgarth. 2009. B7-1/2 (CD80/CD86) direct signaling to B cells enhances IgG secretion. J. Immunol. 183: 7661-7671.
40. Scarsi, M., L. Paolini, D. Ricotta, A. Pedrini, S. Piantoni, L. Caimi, A. Tincani, and P. Airò. 2014. Abatacept reduces levels of switched memory B cells, autoantibodies, and immunoglobulins in patients with rheumatoid arthritis. J. Rheumatol. 41: 666-672.
41. van Lambalgen, R., and M. Jonker. 1987. Experimental allergic encephalomy-elitis in rhesus monkeys: I. Immunological parameters in EAE resistant and susceptible rhesus monkeys. Clin. Exp. Immunol. 68: 100-107.
42. Aubé, B., S. A. Lévesque, A. Paré, É. Chamma, H. Kébir, R. Gorina, M. A. Lécuyer, J. I. Alvarez, Y. De Koninck, B. Engelhardt, et al. 2014. Neu-trophils mediate blood-spinal cord barrier disruption in demyelinating neuro-inflammatory diseases. J. Immunol. 193: 2438-2454.
43. Stoolman, J. S., P. C. Duncker, A. K. Huber, and B. M. Segal. 2014. Site-specific chemokine expression regulates central nervous system inflammation and determines clinical phenotype in autoimmune encephalomyelitis. J. Immunol. 193: 564-570.
44. Simmons, S. B., D. Liggitt, and J. M. Goverman. 2014. Cytokine-regulated neutrophil recruitment is required for brain but not spinal cord inflammation during experimental autoimmune encephalomyelitis. J. Immunol. 193: 555-563.
45. Dale, R. C., C. de Sousa, W. K. Chong, T. C. Cox, B. Harding, and B. G. Neville. 2000. Acute disseminated encephalomyelitis, multiphasic disseminated en-cephalomyelitis and multiple sclerosis in children. Brain 123: 2407-2422.
46. Schwarz, S., A. Mohr, M. Knauth, B. Wildemann, and B. Storch-Hagenlocher. 2001. Acute disseminated encephalomyelitis: a follow-up study of 40 adult patients. Neurology 56: 1313-1318.
47. Franciotta, D., E. Zardini, S. Ravaglia, G. Piccolo, L. Andreoni, R. Bergamaschi, A. Romani, E. Tavazzi, P. Naldi, M. Ceroni, and E. Marchioni. 2006. Cytokines and chemokines in cerebrospinal fluid and serum of adult patients with acute disseminated encephalomyelitis. J. Neurol. Sci. 247: 202-207.
48. Ishizu, T., M. Minohara, T. Ichiyama, R. Kira, M. Tanaka, M. Osoegawa, T. Hara, S. Furukawa, and J. Kira. 2006. CSF cytokine and chemokine profiles in acute disseminated encephalomyelitis. J. Neuroimmunol. 175: 52-58.
49. Maki, T., A. Carville, I. E. Stillman, K. Sato, T. Kodaka, K. Minamimura, N. Ogawa, A. Kanamoto, R. Gottschalk, A. P. Monaco, et al. 2008. SV40 infection associated with rituximab treatment after kidney transplantation in nonhuman primates. Transplantation 85: 893-902.
50. Simon, M. A. 2008. Polyomaviruses of nonhuman primates: implications for research. Comp. Med. 58: 51-56.
51. Simmons, J. H. 2010. Herpesvirus infections of laboratory macaques. J. Immunotoxicol. 7: 102-113.
52. Gulley, M. L., and W. Tang. 2010. Using Epstein-Barr viral load assays to diagnose, monitor, and prevent posttransplant lymphoproliferative disorder. Clin. Microbiol. Rev. 23: 350-366.